Consent given pursuant to sections 14 and 14A to the importation and supply of the therapeutic goods specified by Pfizer Australia

Overview

The Therapeutic Goods Act 1989 is a cornerstone of Australia's regulatory framework for therapeutic goods, which include medicines, medical devices, and blood and blood components. The Act was enacted to address the need for a comprehensive and effective system to regulate the quality, safety, and efficacy of therapeutic goods, thereby protecting public health. The Therapeutic Goods Administration, operating under the auspices of the Department of Health, is the body responsible for administering the Act and ensuring compliance with its provisions. One of the key policy objectives of the Act is to facilitate access to therapeutic goods that are of high quality and safe for use, while also enabling the timely availability of these goods. On 7 January 2016, a delegate of the Secretary of the Department of Health granted consent under sections 14 and 14A of the Therapeutic Goods Act 1989 for the importation and supply of a specific meningococcal group C polysaccharide conjugate vaccine, manufactured by Pfizer Australia Pty Ltd. This consent allowed for the supply of the vaccine with labels bearing the details of the previous sponsor, Baxter Healthcare Pty Ltd, instead of the current sponsor, Pfizer Australia Pty Ltd. This temporary measure was implemented to ensure continuity in the supply of the vaccine, while arrangements were being made to update the labels with the new sponsor's details. The consent was effective from 7 January 2016 until 30 July 2016, and was subject to conditions aimed at maintaining the quality and safety standards of the therapeutic goods supplied.

Scope and Application

The Therapeutic Goods Act 1989 applies to the regulation of therapeutic goods in Australia, covering a wide range of products including medicines, medical devices, blood and blood components, and cosmetics. The Act applies to entities such as manufacturers, importers, sponsors, and suppliers of therapeutic goods, as well as individuals such as health practitioners who supply therapeutic goods in the course of clinical practice. The Act has a national jurisdictional reach and applies to therapeutic goods throughout the Commonwealth of Australia. The Act includes provisions for the assessment, approval, and monitoring of therapeutic goods, as well as for the enforcement of compliance and the imposition of penalties for non-compliance. The Act also provides for the establishment of therapeutic goods regulations and standards, which may specify requirements for the manufacture, presentation, and labelling of therapeutic goods. The Act includes certain exclusions, such as for tobacco products and industrial gases, and certain classes of therapeutic goods may be exempt from some or all of the requirements of the Act. The Act may be extended or restricted in application through subordinate instruments such as regulations and standards.

Key Provisions

Sections 14 and 14A of the Therapeutic Goods Act 1989 (the Act) allow for the importation and supply of therapeutic goods that do not fully conform with specified regulatory requirements under certain conditions. Section 14 provides the mechanism for consent to be given by a delegate of the Secretary of the Department of Health, while Section 14A outlines the circumstances under which such consent may be granted. In this case, section 14 consent was given for the importation and supply of the meningococcal group C polysaccharide conjugate vaccine (NEISVAC-C VACCINE) that did not meet the labelling requirements as stipulated in the Therapeutic Goods Order Number 69, but only for a specified period from 7 January 2016 until 30 July 2016. The obligations imposed by this consent on the entities involved are primarily centred on maintaining the integrity and traceability of the product's supply chain. Specifically, the consent requires that the product be supplied using labels that had previously been approved for the former sponsor, Baxter Healthcare Pty Ltd. Moreover, Pfizer Australia Pty Ltd, the current sponsor, must have arrangements in place to ensure that any queries or complaints regarding the product are promptly referred to them. This condition is crucial to ensure that consumers and healthcare providers have access to the necessary information and support should issues with the product arise. Failure to adhere to the conditions of this consent could lead to various consequences. While the Act does not explicitly state the penalties for non-compliance, breaches of therapeutic goods regulations can generally lead to enforcement actions by the Therapeutic Goods Administration (TGA). These actions may include fines, product recalls, or other administrative measures designed to ensure compliance with the Act. In severe cases, non-compliance could also result in criminal charges, leading to substantial fines or imprisonment, depending on the nature and extent of the breach. In summary, sections 14 and 14A of the Therapeutic Goods Act 1989 provide a framework for allowing the importation and supply of therapeutic goods that do not fully meet regulatory requirements, subject to certain conditions. In this instance, Pfizer Australia Pty Ltd has been granted consent to supply the meningococcal group C vaccine under specific conditions related to labelling and complaint handling. Compliance with these conditions is essential to avoid potential penalties, which could range from administrative actions to criminal charges, depending on the severity of the non-compliance.